Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aKRAS
- Development stage
- Preclinical
- Lead developer
- Oblique Therapeutics
- Modality
- Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
aKRAS is a therapeutic program developed by Oblique Therapeutics that targets various oncogenic mutations of the KRAS protein, including G12D, G12V, and G13D. The program leverages Oblique's proprietary AbMab platform to identify and target hidden, high-affinity epitopes on the KRAS surface, a target traditionally considered undruggable. The aKRAS portfolio is multi-modal, encompassing monoclonal antibodies (aKRAS Ab), small molecule inhibitors, and an oncolytic virus delivery platform developed in collaboration with Circio (formerly Targovax). The most advanced candidate, aKRAS G13D, is in IND-enabling development, while other assets targeting G12V and G12D mutations are in preclinical or lead optimization stages for the treatment of KRAS-mutated solid tumors such as pancreatic, colorectal, and lung cancers.
- Other names
- aKRAS G13DaKRAS G12VaKRAS G12DaKRAS AbaKRAS (Targovax)aKRAS G12D/G12V
02
Targets
Kirsten rat sarcoma viral oncogene homolog mutated proteinKRASG12V (KRAS G12V)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)
Beyond the preview
Go deeper on aKRAS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aKRAS.